Dallas, TX 的 潰瘍性結腸炎 臨床試驗
8 項針對 潰瘍性結腸炎 的研究正在 Dallas（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
招募中2 期
- Ophthalmology Surgery Center of Dallas /ID# 284065, Dallas
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
招募中3 期
- University of Texas - Southwestern Medical Center /ID# 271835, Dallas
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
招募中1 期
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
招募中2 期
- GI Alliance - Dallas - Gaston Avenue, Dallas
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
招募中4 期
- GI Alliance - Digestive Health Associates of Texas, Dallas
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
招募中3 期
- The University of Texas Southwestern Medical Center - Site Number: 8400098, Dallas
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
招募中
- University of Texas Southwestern, Dallas
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
招募中2 期
- Mirador Therapeutics Selected Site, Dallas
其他城市的 潰瘍性結腸炎 試驗
- New York City, NY23 項研究
- Orlando, FL22 項研究
- Miami, FL21 項研究
- Houston, TX17 項研究
- San Antonio, TX16 項研究
- Chicago, IL15 項研究
- Tacoma, WA15 項研究
- San Diego, CA15 項研究
- Tyler, TX14 項研究
- Colorado Springs, CO14 項研究
- Los Angeles, CA13 項研究
- St. Louis, MO13 項研究
Dallas 的其他研究
- 乳癌55 項研究
- 非小細胞肺癌52 項研究
- 轉移性癌症42 項研究
- 心臟衰竭42 項研究
- 癌症（所有類型）37 項研究
- 前列腺癌36 項研究
- 大腸直腸癌33 項研究
- 肥胖症30 項研究
- 卵巢癌28 項研究
- 膀胱癌27 項研究
- 肺癌27 項研究
- 子宮內膜癌24 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月5日。各研究自行設定資格標準；由研究團隊決定參與者資格。